Korean J Med.
2017 Feb;92(1):62-65. 10.3904/kjm.2017.92.1.62.
Osmotic Demyelination Syndrome Resulting from an Unexpected Response to Tolvaptan in a Patient with Heart Failure
- Affiliations
-
- 1Division of Cardiology, Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Korea. parkjrang@gmail.com
- KMID: 2376945
- DOI: http://doi.org/10.3904/kjm.2017.92.1.62
Abstract
- Hyponatremia is commonly encountered in patients with heart failure and has a poor prognosis. Tolvaptan, a novel selective vasopressin V2 receptor blocker, has received attention as an effective drug for treating the syndrome of inappropriate antidiuretic hormone secretion and hypervolemic hyponatremia. However, the safety of tolvaptan in the treatment of hyponatremia is not clear. We experienced a 78-year-old woman with a history of heart failure, atrial fibrillation, and hyponatremia who developed osmotic demyelination syndrome as an unexpected response to treatment with tolvaptan.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Vasopressin Receptor Antagonist, Tolvaptan, for Treating Hyponatremia in Patients with Heart Failure
- Comparison of tolvaptan treatment between patients with the SIADH and congestive heart failure: a single-center experience
- Cortical Laminar Necrosis associated with Osmotic Demyelination Syndrome
- Osmotic Demyelination Syndrome with Recent Chemotherapy in Normonatremic Patient: A Case Report
- V2 Receptor Antagonist; Tolvaptan
